Crown BioScience

STOMACH CANCER IS THE THIRD BIGGEST CANCER KILLER WORLDWIDE, WITH NEW THERAPIES PROVING DIFFICULT TO DEVELOP DUE TO THE DIVERSITY OF THE DISEASE, AND A CLASSIFICATION SYSTEM WHICH HAS LIMITED CLINICAL USE. HOWEVER, NEWLY PUBLISHED RESEARCH HAS BROKEN DOWN STOMACH CANCER INTO 4 BITE SIZED PORTIONS, EACH WITH THEIR OWN DISTINGUISHING FEATURES, WITH THE HOPE… Read more »

DUE TO INCREASING OBESITY LEVELS, INACTIVITY, AND AN AGING POPULATION WORLDWIDE THE PREVALENCE OF TYPE 2 DIABETES HAS REACHED EPIDEMIC PROPORTIONS. THE WORLD HEALTH ORGANIZATION REPORTS THAT 347 MILLION PEOPLE GLOBALLY HAVE DIABETES, WITH TYPE 2 ACCOUNTING FOR 90% OF CASES. WHILST TYPE 2 DIABETES PREVALENCE RATES HAVE BEEN INCREASING IN THE US RECENTLY, (FROM… Read more »

IMMUNOTHERAPY IS AT THE FOREFRONT OF ONCOLOGY RESEARCH, WITH MANY COMPANIES FOCUSING ON THE SAME SPECIFIC TARGETS IN MULTIPLE CANCER TYPES. THE RACE HAS BEEN ON FOR THE FIRST US APPROVAL OF AN ANTI-PD-1 AGENT, AND MERCK HAVE PROVED VICTORIOUS WITH THE FDA SAYING YES TO KEYTRUDA (PEMBROLIZUMAB) IN ADVANCED MELANOMA JUST LAST WEEK. Anti… Read more »

PERSONALIZED MEDICINE IS THE FUTURE OF CANCER THERAPY, AND MANY TECHNIQUES ARE BEING USED TO DRIVE FORWARD RESEARCH IN THIS AREA. PATIENT-DERIVED XENOGRAFT (PDX) MODELS ARE AT THE FOREFRONT OF PERSONALIZED MEDICINE RESEARCH IN HUMAN SURROGATE TRIALS, BUT OTHER APPROACHES TO USING PDX ARE ALSO BEING PIONEERED WHICH MAY NOT BRING THE FULL PATIENT BENEFIT… Read more »